PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32761423-4	2021	To overcome these limitations and further improve therapeutic efficacy, we designed IBI322, a CD47/PD-L1 bispecific antibody which attenuated CD47 activity in monovalent binding and blocked PD-L1 activity in bivalent binding.	ibi322	84-90	CD47 molecule	Homo sapiens	94-98	
32761423-4	2021	To overcome these limitations and further improve therapeutic efficacy, we designed IBI322, a CD47/PD-L1 bispecific antibody which attenuated CD47 activity in monovalent binding and blocked PD-L1 activity in bivalent binding.	ibi322	84-90	CD47 molecule	Homo sapiens	142-146	
32761423-5	2021	IBI322 selectively bound to CD47+PD-L1+ tumor cells, effectively inhibited CD47-SIRPalpha signal and triggered strong tumor cell phagocytosis in vitro, but only with minimal impact on CD47 single positive cells such as human RBCs.	ibi322	0-6	CD47 molecule	Homo sapiens	28-32	
32761423-5	2021	IBI322 selectively bound to CD47+PD-L1+ tumor cells, effectively inhibited CD47-SIRPalpha signal and triggered strong tumor cell phagocytosis in vitro, but only with minimal impact on CD47 single positive cells such as human RBCs.	ibi322	0-6	CD47 molecule	Homo sapiens	75-79	
32761423-5	2021	IBI322 selectively bound to CD47+PD-L1+ tumor cells, effectively inhibited CD47-SIRPalpha signal and triggered strong tumor cell phagocytosis in vitro, but only with minimal impact on CD47 single positive cells such as human RBCs.	ibi322	0-6	CD47 molecule	Homo sapiens	75-79	
32275842-2	2020	Herein, positron emission tomography (PET) imaging with 89Zr-labeled IBI322, an anti-CD47/PD-L1 BsAb, was used to optimize the safety and effective therapy dose.	ibi322	69-75	CD47 molecule	Homo sapiens	85-89